Total Payments
$2,776
2019 Payments
$23.38
Companies
21
Transactions
133
Payment Breakdown by Category
Food & Beverage$1,444 (52.0%)
Research$1,331 (48.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,444 | 124 | 52.0% |
| Unspecified | $1,331 | 9 | 48.0% |
Payments by Type
General
$1,444
124 transactions
Research
$1,331
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,677 | 41 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $190.66 | 7 | $0 (2017) |
| PFIZER INC. | $152.30 | 11 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $149.61 | 32 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $123.18 | 9 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $80.80 | 5 | $0 (2018) |
| Genentech USA, Inc. | $76.23 | 5 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $53.24 | 4 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $35.60 | 2 | $0 (2017) |
| Advanced Respiratory, Inc | $31.02 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $23.38 | 2 | Sunovion Pharmaceuticals Inc. ($23.38) |
| 2018 | $364.49 | 31 | GlaxoSmithKline, LLC. ($69.68) |
| 2017 | $2,388 | 100 | GlaxoSmithKline, LLC. ($1,608) |
All Payment Transactions
133 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/12/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: RESPIRATORY | ||||||
| 05/22/2019 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $6.77 | General |
| Category: RESPIRATORY | ||||||
| 12/03/2018 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.96 | General |
| Category: Cardiovascular | ||||||
| 11/12/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: Respiratory | ||||||
| 09/04/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/31/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $5.82 | General |
| Category: Respiratory | ||||||
| 07/16/2018 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.86 | General |
| Category: Cardiovascular | ||||||
| 07/11/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/27/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/18/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/26/2018 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: RESPIRATORY | ||||||
| 04/20/2018 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: RESPIRATORY | ||||||
| 04/10/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $1.57 | General |
| Category: Respiratory | ||||||
| 04/09/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 04/09/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: Respiratory | ||||||
| 04/06/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $4.08 | General |
| Category: Respiratory | ||||||
| 04/04/2018 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: RESPIRATORY | ||||||
| 03/28/2018 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 03/22/2018 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: CARDIOVASCULAR DISORDERS | ||||||
| 03/16/2018 | Advanced Respiratory, Inc | The Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Airway Clearance Device | ||||||
| 03/15/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/14/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $0.76 | General |
| Category: Respiratory | ||||||
| 03/12/2018 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $19.13 | General |
| Category: Cardiovascular | ||||||
| 03/06/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $1.31 | General |
| Category: Respiratory | ||||||
| 03/01/2018 | Novartis Pharmaceuticals Corporation | XOLAIR (Biological) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 24 month double blind randomised parallel group study to determine the effect of Anoro on symptoms vs Tiotropium | GlaxoSmithKline, LLC. | $1,331 | 9 |
About Dr. John Best, MD
Dr. John Best, MD is a Pulmonary Disease healthcare provider based in Chesterfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053429977.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Best, MD has received a total of $2,776 in payments from pharmaceutical and medical device companies, with $23.38 received in 2019. These payments were reported across 133 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,444).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Chesterfield, MO
- Active Since 08/29/2006
- Last Updated 06/15/2012
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1053429977
Products in Payments
- ANORO (Drug) $1,411
- ELIQUIS (Drug) $137.04
- OFEV (Drug) $134.49
- NUCALA (Biological) $124.99
- XARELTO (Drug) $123.18
- BREO (Drug) $104.44
- CHANTIX (Drug) $96.06
- Esbriet (Biological) $65.25
- BROVANA (Drug) $47.84
- STIOLTO (Drug) $43.70
- LONHALA MAGNAIR (Drug) $41.66
- XOLAIR (Biological) $39.42
- UTIBRON (Drug) $37.90
- TRELEGY ELLIPTA (Drug) $36.87
- PRALUENT (Drug) $35.60
- Prolastin-C (Biological) $26.17
- SMARTVEST (Device) $23.90
- RAPIVAB (Biological) $22.76
- Utibron (Drug) $22.21
- TUDORZA PRESSAIR (Drug) $18.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Chesterfield
Dr. Bobby Shah, Md, MD
Pulmonary Disease — Payments: $210,590
Pulmonary Disease $210,590
Kristen Fisher, M.d, M.D
Pulmonary Disease — Payments: $14,948
Pulmonary Disease $14,948
Dr. Steven Brown, M.d, M.D
Pulmonary Disease — Payments: $614.58
Pulmonary Disease $614.58
Adnan Habib, Md, MD
Pulmonary Disease
Pulmonary Disease
Dr. Rhody Eisenstein, Md, MD
Pulmonary Disease
Pulmonary Disease